Ehave, Inc. (OTC Pink: EHVVF), a leader in the research and distribution of novel therapeutics, has reached a new milestone this January 4th. The Company has applied to upgrade its OTC status to OTCQB. According to www.investopedia.com, “The OTCQB, also called “The Venture Market,” is the middle tier of the over-the-counter (OTC) market for U.S. stocks. It was created in 2010 and consisted mainly of early-stage and developing U.S. and International companies that are not yet able to qualify for the OTCQX but are not as speculative as the lowest-tier Pink Sheets.” (1) To qualify for the designation, a company must “be current in their reporting, undergo annual verification and certification, meet a $0.01 bid test, and may not be in bankruptcy.” (ibid.)
In addition, Ehave Inc. has applied to the Canadian Securities Exchange (CSE). According to www.thecse.com, A company must be a “Reporting Issuer in good standing in any Canadian jurisdiction” and “generally must have a public float of at least 500,000 freely-tradeable shares consisting of at least 150 public holders with at least a board lot each of the security.” (2) Ongoing requirements that companies must meet to continue being listed include the responsibility to “Report and file documents as required by applicable securities law (remain in good standing in each reporting province); post required disclosure documents and forms at www.thecse.com; provide monthly activity reports and periodically certify that the Issuer complies with applicable securities law; pay the monthly maintenance fee;” and “update the Listing Statement on an annual basis.”
Ehave Inc. describes itself as “a healthcare company developing the next generation of digital solutions for stakeholders in the medical cannabis and mental health sectors. Ehave’s health informatics platform efficiently captures high-quality, objective user data. By bridging the substantial information gap in healthcare, while at the same time facilitating the deployment of novel digital assessment and remediation tools, we believe that we will empower users and improve patient care. Ehave focuses on serving the needs of stakeholders in the medical cannabis industry and in mental health, two sectors that we believe will benefit greatly from improved data collection and analysis.” (3)
One of the more exciting innovations from Ehave Inc. is its KetaDASH platform. KetaDASH offers home delivery for those who have been prescribed Ketamine infusions. Ketamine is currently being prescribed mainly as a less addictive alternative to other pain medication but shows promise in clinical trials of treating conditions as wide-ranging as depression and ADHD. In their own words, “KetaDASH instantly connects you with highly skilled nurses and lets you get your ketamine therapy under expert supervision.” (4)
Ehave provides additional information through its press release (5):
Additional Ehave Inc. Information
We are truly grateful for the support of EHVVF shareholders! Please join the conversation on our Ehave supporter’s telegram group at https://t.me/EhaveInc.
The Company posts important information and updates through weekly videos from the official Company YouTube channel https://www.youtube.com/channel/UCnyW1mgMd0qmYkEMq3O6FWA.
About Ehave, Inc.
Ehave, Inc. (EHVVF) is a leader in digital therapeutics and developer of KetaDASH, a home delivery platform for patients who have been prescribed Ketamine infusions. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. The Ehave Telemetry Portal is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high-quality, safe, and effective data-driven involvement with intelligent and accessible tools. Ehave also owns 75.77% of psychedelic company 20/20 Global’s outstanding shares. Additional information on Ehave can be found on the Company’s website at: www.ehave.com.
KetaDASH is a subsidiary of Ehave that provides a home delivery platform for medical practitioners to administer Ketamine intravenously to patients who have been prescribed Ketamine at the patients’ home. Ketamine is currently used to help ease pain and allows sedatives to be effective at lower doses, lessening the amount of potentially addictive pain medication required after certain medical procedures. Ketamine is now being studied as a treatment for major depression, though it has not yet been approved by the FDA to treat depression. The KetaDASH platform includes software, staffing, protocols, and equipment, as well as a smart and intuitive dashboard that will provide clients and medical professionals with detailed insight on how Ketamine therapy is working. Patients will be able to create a profile, check the availability of administering nurses, and schedule appointments. Additional information on KetaDASH can be found on the Company’s website at: www.ketadash.com.
Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.